AbbVie Inc. (NYSE:ABBV) Shares Bought by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. boosted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 5.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 154,745 shares of the company's stock after acquiring an additional 7,684 shares during the period. AbbVie comprises about 0.9% of Dana Investment Advisors Inc.'s holdings, making the stock its 15th biggest holding. Dana Investment Advisors Inc.'s holdings in AbbVie were worth $27,498,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Vision Financial Markets LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at about $160,000. Arizona State Retirement System raised its position in shares of AbbVie by 1.3% in the fourth quarter. Arizona State Retirement System now owns 513,008 shares of the company's stock valued at $91,162,000 after buying an additional 6,690 shares during the last quarter. Verdence Capital Advisors LLC raised its position in shares of AbbVie by 14.0% in the fourth quarter. Verdence Capital Advisors LLC now owns 25,453 shares of the company's stock valued at $4,523,000 after buying an additional 3,127 shares during the last quarter. Sound Financial Strategies Group LLC raised its position in shares of AbbVie by 5.3% in the fourth quarter. Sound Financial Strategies Group LLC now owns 1,197 shares of the company's stock valued at $213,000 after buying an additional 60 shares during the last quarter. Finally, Vantage Financial Partners LLC raised its position in shares of AbbVie by 11.2% in the fourth quarter. Vantage Financial Partners LLC now owns 10,945 shares of the company's stock valued at $1,945,000 after buying an additional 1,105 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. BMO Capital Markets increased their target price on shares of AbbVie from $208.00 to $215.00 and gave the company an "outperform" rating in a research report on Monday, February 3rd. Daiwa Capital Markets cut shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $180.00 target price for the company. in a research report on Thursday, December 5th. Piper Sandler Companies reiterated an "overweight" rating and issued a $220.00 target price on shares of AbbVie in a research report on Tuesday, December 17th. Wells Fargo & Company increased their target price on shares of AbbVie from $210.00 to $240.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Citigroup upped their price objective on shares of AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $211.45.

Insider Activity

In related news, EVP Perry C. Siatis sold 5,778 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the sale, the executive vice president now owns 22,381 shares of the company's stock, valued at $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Kevin K. Buckbee sold 1,800 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,439 shares of company stock valued at $11,377,057. 0.25% of the stock is currently owned by company insiders.

AbbVie Trading Up 1.9 %

Shares of ABBV stock opened at $211.61 on Thursday. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The firm has a market cap of $373.57 billion, a PE ratio of 88.17, a price-to-earnings-growth ratio of 1.62 and a beta of 0.58. The company has a 50-day moving average of $186.27 and a two-hundred day moving average of $187.31. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $215.66.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter in the previous year, the business posted $2.79 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Tuesday, April 15th. AbbVie's payout ratio is 273.33%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.